THURSDAY, March 6, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a ...

The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

The following is a summary of “Reducing time delays and enhancing reperfusion eligibility related to stroke suspicion by the ...

Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

Brazilian researchers have developed a cell phone application that helps rehabilitate people who have suffered a stroke.

Learn the key differences between stroke and migraine symptoms, from onset speed to pain patterns, and know exactly when to ...

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells are reprogrammed to ...

Chronic stress can increase young women's risk of stroke, a new study says. Moderate stress increases risk of stroke by 78% ...

The ambulance would be the latest addition to Florida’s first mobile stroke treatment unit network, which speeds care to ...

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according ...